3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Pancreatic Neoplasms
6
Uterine Cervical Neoplasms
2
Thyroid Neoplasms
2
Stomach Neoplasms
2
Ovarian Neoplasms
2
Melanoma
2
Lung Neoplasms
2
Glioblastoma
2
Uveal Melanoma
1
Uterine Neoplasms
1
Urinary Bladder Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Phase IB
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mesonephric Gynecologic Cancer
1
Lymphoma
1
Low-Grade Serous Ovarian Cancer
1
Low Grade Serous Ovarian Cancer
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Glioma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
pembrolizumab
243
Carboplatin
211
Pemetrexed
177
Cisplatin
131
Paclitaxel
113
Nivolumab
101
Docetaxel
87
osimertinib
85
durvalumab
78
Specimen Handling
56
atezolizumab
55
Gemcitabine
52
Drug Therapy
52
Magnetic Resonance Spectroscopy
50
Radiosurgery
48
Radiotherapy
47
Ipilimumab
41
130-nm albumin-bound paclitaxel
39
cemiplimab
38
Bevacizumab
34
Cetuximab
30
tislelizumab
29
amivantamab
22
Taxes
22
Platinum Compounds
20
Blood Specimen Collection
20
Immunotherapy
18
Immune Checkpoint Inhibitors
18
Radiation
17
Erlotinib Hydrochloride
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Non-Small-Cell Lung
×
defactinib
×
1 year
×
Clear all
NCT05074810
2026-01-12
RAMP203
Verastem, Inc.
Phase 1/2
Active not recruiting
153 enrolled